{"disease":{"id":"mucopolysaccharidosis-mps-iv-a","name":"Mucopolysaccharidosis, MPS-IV-A","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"elosulfase-alfa","indication_name":"Mucopolysaccharidosis, MPS-IV-A","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhgalns","generic_name":"ELOSULFASE ALFA","company_name":"BioMarin","drug_phase":"marketed","molecular_target":"N-acetylgalactosamine-6-sulfatase","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":55,"revenue":"500","mechanism":"VIMIZIM provides exogenous N-acetylgalactosamine-6-sulfatase to increase the catabolism of GAGs KS and C6S in lysosomes."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07361536","title":"Cardiac Structure and Function in MPS","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Children's Hospital of Orange County","has_results":false},{"nct_id":"NCT05284006","title":"Non-invasive Functional Assessment and Pathogenesis of Morquio A","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Nemours Children's Clinic","has_results":false},{"nct_id":"NCT03632213","title":"Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}